FLT3 and acute myeloid leukemia: An anchored matching-adjusted comparison of the RATIFY and QuANTUM-First trials suggested that midostaurin and quizartinib offer broadly comparable OS benefits when combined with standard 7+3 induction chemotherapy in newly diagnosed FLT3-ITD AML, despite differences in study designs and patient populations [45].